Form 4: Opus Genetics Director Acquires Stock Options
SEC Form 4 Filing
Adrienne L Graves, a director at Opus Genetics, acquired stock options for 172,874 shares on October 22, 2024.
Summary
- On October 22, 2024, Adrienne L Graves, a director of Opus Genetics, Inc., acquired stock options.
- The options grant the right to buy 172,874 shares of common stock at an exercise price of $1.33 per share.
- The options vest in three equal annual installments starting from the grant date and expire on October 21, 2034.
- Following the transaction, Graves directly owns 172,874 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into insider transactions.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/22/2024 | Date of stock option transaction |
| 10/21/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.